GT BIOPHARMA, INC. Income (Loss) from Equity Method Investments
GT BIOPHARMA, INC. (GTBP) reported Income (Loss) from Equity Method Investments of $250.00 thousand for the 0-month period ending 2010-11-08, per its 10-Q/A filed 2021-12-29.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2021-12-29
- 2010-11-08: Income (Loss) from Equity Method Investments 0 month $250.00K.
| Period end | Income (Loss) from Equity Method Investments 0 month |
|---|---|
| 2010-11-08 | $250.00K 10-Q/A · filed 2021-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |